Dual-time-point [18F]-FDG PET/CT in the diagnostic evaluation of suspicious breast lesions(327 views visite) Caprio MG, Cangiano A, Imbriaco M, Soscia F, Di Martino G, Farina A, Avitabile G, Pace L, Forestieri P, Salvatore M
Radiol Med (ISSN: 0033-8362, 1826-6983, 1826-6983electronic), 2010 Mar; 115(2): 215-224.
Keywords Parole chiave: [18f]-Fdg Pet Ct, Breast Carcinoma, Dual-Phase Acquisition, Lesion Identification, Diagnostic Agent, Fluorodeoxyglucose F 18, Radiopharmaceutical Agent, Article, Breast Tumor, Computer Assisted Diagnosis, Computer Assisted Tomography, Female, Human, Mammography, Methodology, Middle Aged, Positron Emission Tomography, Radiography, Scintiscanning, Sensitivity And Specificity, Breast Neoplasms, Image Interpretation, Computer-Assisted, Positron-Emission Tomography, X-Ray Computed, [18f] -Fdg Pet Ct,
Affiliations Affiliazioni: *** IBB - CNR ***
Fondazione S. D. N., Istituto di Ricerca Diagnostica e Nucleare, Via Pansini 5, Napoli 80131, Italy Dipartimento di Scienze Biomorfologiche e Funzionali, Institute of Bio-structure and Bio-imaging, Via Posillipo 196, Napoli 80123, Italy Dipartimento di Chirurgia Generale, Geriatrica, Oncologica e Tecnologie Avanzate, Università Degli Studi di Napoli Federico II, Napoli, Italy
References Riferimenti: Jemal, A., Siegel, R., Ward, E., Cancer statistics (2007) CA Cancer J Clin, 57, pp. 43-66. , 10.3322/canjclin.57.1.43 1723703
Schirrmeister, H., Kuhn, T., Guhlmann, A., Fluorine-18-2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: Comparison with the standard staging procedures (2001) Eur J Nucl Med, 28, pp. 351-358. , 10.1007/s002590000448 1:CAS:528:DC%2BD3MXitFeiu7o%3D 11315604
Eubank, W.B., Mankoff, D.A., Evolving role of positron emission tomography in breast cancer imaging (2005) Seminars in Nuclear Medicine, 35 (2), pp. 84-99. , DOI 10.1053/j.semnuclmed.2004.11.001, Breast Disease
Matthies, A., Hicheson, M., Cuchiara, A., Alavi, A., Dual time point 18F-FDG PET for the evaluation of pulmonary nodules (2002) J Nucl Med, 43, pp. 871-875. , 12097455
Kumar, R., Loving, V.A., Chauhan, A., Potential of dual-time-point imaging to improve breast cancer diagnosis with 18F-FDG PET (2005) J Nucl Med, 46, pp. 1819-1824. , 16269595
Mavi, A., Urhan, M., Yu, J.Q., Dual Time point 18F-FDG-PET imaging detects breast cancers with high sensitivity and correlates well with histologic subtypes (2006) J Nucl Med, 47, pp. 1440-1446. , 16954551
(1995) Breast Imaging Reporting and Data System (BI-RADS), , American College of Radiology. American College of Radiology Reston
(1992) Manual for the Staging of Cancer, , B.J. Kennedy (eds). Lippincott Philadelphia
Buck, A., Schirrmeister, H., Kuhn, T., Shen, C., Kalker, T., Kotzerke, J., Dankerl, A., Mattfeldt, T., FDG uptake in breast cancer: Correlation with biological and clinical prognostic parameters (2002) European Journal of Nuclear Medicine and Molecular Imaging, 29 (10), pp. 1317-1323. , DOI 10.1007/s00259-002-0880-8
Lowe, V.J., Fletcher, J.W., Gobar, L., Lawson, M., Kirchner, P., Valk, P., Karis, J., Coleman, R.E., Prospective investigation of positron emission tomography in lung nodules (1998) Journal of Clinical Oncology, 16 (3), pp. 1075-1084
Dewan, N.A., Gupta, N.C., Redepenning, L.S., Diagnostic efficacy of FDG-PET imaging in solitary pulmonary nodules. Potential role in evaluation and management (1993) Chest, 104, pp. 997-1002. , 10.1378/chest.104.4.997 1:STN:280:DyaK2c%2FgvVWktw%3D%3D 8404239
Zhuang, H., Pourdehnad, M., Lambright, E.S., Dual time point FDG PET imaging for differentiating malignant form inflammatory processes (2001) J Nucl Med, 42, pp. 1412-1417. , 1:STN:280:DC%2BD3Mvptlersg%3D%3D 11535734
Hustinx, R., Smith, R.J., Benard, F., Rosenthal, D.I., Machtay, M., Farber, L.A., Alavi, A., Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: A potential method to differentiate malignancy from inflammation and normal tissue in the head and neck (1999) European Journal of Nuclear Medicine, 26 (10), pp. 1345-1348. , DOI 10.1007/s002590050593
Koyama, K., Okamura, T., Kawabe, J., The usefulness of FDG-PET images obtained 2 hours after intravenous injection in liver tumor (2002) Ann Nucl Med, 16, pp. 169-176. , 10.1007/BF02996297 12126041
Torizuka, T., Tamaki, N., Inokuma, T., In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG PET (1995) J Nucl Med, 36, pp. 1811-1817. , 1:STN:280:DyaK28%2FgslKgsw%3D%3D 7562048
Nishiyama, Y., Yamamoto, Y., Monden, T., Sasakawa, Y., Tsutsui, K., Wakabayashi, H., Ohkawa, M., Evaluation of delayed additional FDG PET imaging in patients with pancreatic tumour (2005) Nuclear Medicine Communications, 26 (10), pp. 895-901. , DOI 10.1097/00006231-200510000-00008
Avril, N., Rosè, C.A., Schelling, M., Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: Use and limitations (2000) J Clin Oncol, 18, pp. 3495-3502. , 1:STN:280:DC%2BD3M%2Fhsl2hsA%3D%3D 11032590
Kumar, R., Chauhan, A., Zhuang, H., Chandra, P., Schnall, M., Alavi, A., Standardized uptake values of normal breast tissue with 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography: Variations with age, breast density, and menopausal status (2006) Molecular Imaging and Biology, 8 (6), pp. 355-362. , DOI 10.1007/s11307-006-0060-5
Hellwig, D., Graeter, T.P., Ukena, D., Groeschel, A., Sybrecht, G.W., Schaefers, H.-J., Kirsch, C.-M., 18F-FDG PET for mediastinal staging of lung cancer: Which SUV threshold makes sense? (2007) Journal of Nuclear Medicine, 48 (11), pp. 1761-1766. , http://jnm.snmjournals.org/cgi/reprint/48/11/1761, DOI 10.2967/jnumed.107.044362
Murthy, K., Aznar, M., Thompson, C.J., Results of preliminary clinical trials of the positron emission mammography system PEM-I: A dedicated breast imaging system producing glucose metabolic images using FDG (2000) J Nucl Med, 41, pp. 1851-1858. , 1:STN:280:DC%2BD3M%2FktFOltw%3D%3D 11079494
Tafra, L., Positron emission tomography (PET) and mammography (PEM) for breast cancer: Importance to surgeons (2007) Annals of Surgical Oncology, 14 (1), pp. 3-13. , DOI 10.1245/s10434-006-9019-7
Weinberg, I.N., Beylin, D., Zavarzin, V., Positron emission mammography: High-resolution biochemical breast imaging (2005) Technol Cancer Res Treat, 4, pp. 55-60. , 15649088
Eubank, W. B., Mankoff, D. A., Evolving role of positron emission tomography in breast cancer imaging (2005) Seminars in Nuclear Medicine, 35 (2), pp. 84-99. , DOI 10. 1053/j. semnuclmed. 2004. 11. 001, Breast Disease
(1995) Breast Imaging Reporting and Data System (BI-RADS), , American College of Radiology. American College of Radiology Reston
(1992) Manual for the Staging of Cancer, , B. J. Kennedy (eds). Lippincott Philadelphia
Lowe, V. J., Fletcher, J. W., Gobar, L., Lawson, M., Kirchner, P., Valk, P., Karis, J., Coleman, R. E., Prospective investigation of positron emission tomography in lung nodules (1998) Journal of Clinical Oncology, 16 (3), pp. 1075-1084
Dewan, N. A., Gupta, N. C., Redepenning, L. S., Diagnostic efficacy of FDG-PET imaging in solitary pulmonary nodules. Potential role in evaluation and management (1993) Chest, 104, pp. 997-1002. , 10. 1378/chest. 104. 4. 997 1: STN: 280: DyaK2c%2FgvVWktw%3D%3D 8404239
Avril, N., Ros, C. A., Schelling, M., Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: Use and limitations (2000) J Clin Oncol, 18, pp. 3495-3502. , 1: STN: 280: DC%2BD3M%2Fhsl2hsA%3D%3D 11032590
Weinberg, I. N., Beylin, D., Zavarzin, V., Positron emission mammography: High-resolution biochemical breast imaging (2005) Technol Cancer Res Treat, 4, pp. 55-60. , 15649088
Dual-time-point [18F]-FDG PET/CT in the diagnostic evaluation of suspicious breast lesions
Petraglia F, Singh AA, Carafa V, Nebbioso A, Conte M, Scisciola L, Valente S, Baldi A, Mandoli A, Petrizzi VB, Ingenito C, De Falco S, Cicatiello V, Apicella I, Janssen-megens EM, Kim B, Yi G, Logie C, Heath S, Ruvo M, Wierenga ATJ, Flicek P, Yaspo ML, Della Valle V, Bernard O, Tomassi S, Novellino E, Feoli A, Sbardella G, Gut I, Vellenga E, Stunnenberg HG, Mai A, Martens JHA, Altucci L * Combined HAT/EZH2 modulation leads to cancer-selective cell death(199 visite) Oncotarget (ISSN: 1949-2553electronic, 1949-2553linking), 2018 May 22; 9(39): 25630-25646. Impact Factor:5.008 DettagliEsporta in BibTeXEsporta in EndNote
Santulli G, Cipolletta E, Sorriento D, Del Giudice C, Anastasio A, Monaco S, Maione AS, Condorelli G, Puca A, Trimarco B, Illario M, Iaccarino G * CaMK4 gene deletion induces hypertension(277 visite) J Am Heart Assoc Journal Of The American Heart Association (ISSN: 2047-9980), 2012; 1(4): N/D-N/D. Impact Factor:2.882 DettagliEsporta in BibTeXEsporta in EndNote
Antonini A, Vitale C, Barone P, Cilia R, Righini A, Bonuccelli U, Abbruzzese G, Ramat S, Petrone A, Quatrale R, Marconi R, Ceravolo R, Stefani A, Lopiano L, Zappia M, Capus L, Morgante L, Tamma F, Tinazzi M, Colosimo C, Guerra UP, Valzania F, Fagioli G, Distefano A, Bagnato A, Feggi L, Anna S, Maria Teresa Rosaria De Cr, Nobili F, Mazzuca N, Baldari S, Eleopra R, Bestetti A, Benti R, Varrone A, Volterrani D, Massa R, Stocchi F, Schillaci O, Dore F, Zibetti M, Castellano G, Battista SG, Giorgetti G * The relationship between cerebral vascular disease and parkinsonism: The VADO study(406 visite) Parkinsonism Relat D (ISSN: 1353-8020, 1873-5126, 1873-5126electronic), 2012; 18(6): 775-780. Impact Factor:3.274 DettagliEsporta in BibTeXEsporta in EndNote
Malvindi MA, Greco A, Conversano F, Figuerola A, Corti M, Bonora M, Lascialfari A, Doumari HA, Moscardini M, Cingolani R, Gigli G, Casciaro S, Pellegrino T, Ragusa A * MR Contrast Agents(224 visite) Small Animal Imaging, 2011 Jul 8; 21(13): 2548-2555. Impact Factor:1.784 DettagliEsporta in BibTeXEsporta in EndNote
Bruni AC, Bernardi L, Colao R, Rubino E, Smirne N, Frangipane F, Terni B, Curcio SA, Mirabelli M, Clodomiro A, Di Lorenzo R, Maletta R, Anfossi M, Gallo M, Geracitano S, Tomaino C, Muraca MG, Leotta A, Lio SG, Pinessi L, Rainero I, Sorbi S, Nee L, Milan G, Pappata S, Postiglione A, Abbamondi N, Forloni G, St George Hyslop P, Rogaeva E, Bugiani O, Giaccone G, Foncin JF, Spillantini MG, Puccio G * Worldwide distribution of PSEN1 Met146Leu mutation: A large variability for a founder mutation(399 visite) Neurology (ISSN: 0028-3878, 1526-632x, 1526-632xelectronic), 2010 Mar 9; 74(10): 798-806. Impact Factor:8.017 DettagliEsporta in BibTeXEsporta in EndNote